Articles
A Facebook No-No(vartis)
August 11, 2010
By Lori Clapper, Web Editor
The FDA recently sent a warning letter to Novartis regarding the "Facebook Share" widget on the company's U.S. website for the leukemia drug Tasigna. According to the letter, Novartis' use of this app to promote the medication did not comply with FDA regulations. The widget enabled visitors to share information about Tasigna that FDA called "misleading" because "it makes representations about the efficacy of Tasigna, but fails to communicate any risk information associated with the use of this drug."
In response to the FDA letter, Novartis did take down the share widget.
